Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

By sjmartinez • February 14, 2023

Friend BD, Broglie L, Logan BR, Chhabra S, Bupp C, Schiller G, Beitinjaneh A, Perez MAD, Guilcher GMT, Hashem H, Hildebrandt GC, Krem MM, Lazarus HM, Nishihori T, Nusrat R, Rotz SJ, Wirk B, Wieduwilt M, Pasquini M, Savani BN, Stadtmauer EA, Sorror ML, Thakar MS. Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 Feb;29(2):123.e1-123.e10. doi: 10.1016/j.jtct.2022.11.019. Epub 2022 Nov 26. PMID: 36442769; PMCID: PMC9911376.

Tags: Adolescents and young adults (AYA), Allogeneic hematopoietic cell transplantation, comorbidities, HCT-CI, Hematologic malignancies, Hematology/Oncology, Pediatrics, Publications

Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD

Goldberg SB, Ahn MJ, Baik C, De Castro Carpeño J, Cho BC, de Langen AJ, Fidler MJ, Goldman JW, Grønberg BH, Akamatsu H, Kim SW,[...]

Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial

Waks AG, Segui E, Li T, Lipsyc-Sharf M, Kallfelz E, DiLullo M, Patel A, Rahman T, Junkins K, Rahee H, Frey AM, Kelly E, Stalteri[...]

Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape

Lipsyc-Sharf M, Hurvitz SA. Current Management of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in a Changing Landscape. J Clin Oncol. 2026 Jul 13:JCO2600672.[...]